CureVac Q3 2025 Earnings Report

CureVac EPS Results

• Actual EPS: -$0.10
• Consensus EPS: -$0.17
• Beat/Miss: Beat by +$0.07
• One Year Ago EPS: N/A

CureVac Revenue Results

• Actual Revenue: $63.53 million
• Expected Revenue: $21.40 million
• Beat/Miss: Beat by +$42.13 million
• YoY Revenue Growth: N/A

CureVac Announcement Details

• Quarter: Q3 2025
• Date: 11/24/2025
• Time: Before Market Opens
• Conference Call Date: Monday, November 24, 2025
• Conference Call Time: 7:00AM ET

CureVac (NASDAQ:CVAC) is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs. Its RNActive® platform underpins several vaccine candidates, including those targeting seasonal influenza, rabies and other viral pathogens. In oncology, the company is advancing individualized neoantigen vaccines and combination immunotherapies designed to stimulate targeted anti-tumor immune responses. Over the years, CureVac has entered collaborations with pharmaceutical partners to co-develop next-generation mRNA products, most notably a strategic partnership announced in 2021 focused on seasonal influenza vaccines.

CureVac maintains research facilities in Germany and actively engages with the global scientific community through alliances and academic collaborations. The company also operates a presence in the United States to support clinical development and regulatory interactions. Leadership is led by Franz-Werner Haas, who has served as Chief Executive Officer since 2018, guiding CureVac’s transition from pioneering research to commercialization readiness. Supported by an interdisciplinary team of biologists, chemists and clinicians, the company continues to expand its platform capabilities and explore new indications for mRNA therapeutics.